Test was designed to report a NEGATIVE or POSITIVE result; the numeric value is irrelevant. That's why I'm extremely concerned that Northwell has chosen to provide a value; it is assay malpractice plain and simple.
The cutoff is determined by testing hundreds of negative patients to develop a "Normal Distribution". Then you start running known positives, as many as you can get your hands on. IF the Assay Gods are smiling favorably upon you, the signals of the 2 populations will be separated by at least 5 Std Deviations of the Normal Population's. If the Gods really love you, it will be 9 Std Devs or higher, this is Assay Nirvana. At that level, the odds of a false result are minimized.
If the number of Std Deviations is less than 5, you start working with the formulation to get better signal separation between the Normal and Sick populations. After you think you've got the cutoff correct you validate that by testing sensitivity and specificity by running samples that you know could be difficult to detect to test your sensitivity and samples that could give you a false positive to test your specificity. Finally you get a hold of timed samples from a patient that were taken over a few weeks that also have corresponding PCR (diagnostic tests) so you can see if and when the person developed antibodies. Hit any snags during this testing, then it's reformulation time.
NEVER in this process do you correlate the amount of antibody to the signal. There are 100s of reasons why not, but suffice it to say that a QUANTITATIVE Antibody Assay is a major, complex challenge since you may have hundreds of COVID-19 antibodies, each with a vastly different activity. For example if you have 10 mg of low reactivity AbX and 1 ug of high reactivity AbY, you might think your reaction is due to AbX, when it's really AbY driving the reactivity.
A quantitative Ab assay has no diagnostic value when trying to determine if someone is positive or negative. However it is crucial for determining which patients have high-reactivity antibodies for a possible treatment for others. Then you begin testing for reactivity for specific epitopes by linear dilutions, a very labor-intensive testing protocol, but essential to determine donors that can fulfill the need for plasma donations with adequate titers for treating other patients.
There should be no confusion regarding the amount of antibody and the protection you have. The assay only determines IF the person has a level of COVID-19 indicative of a former infection. It says nothing about the efficacy of these antibodies, especially since nobody at this time knows what antibodies and what titer are needed to prevent COVID-19. As the vaccine candidates go through clinical trials, these data will be generated, along with the studies transfusing plasma from cured COVID-19 patients into sick patients.